Related Experiment Video
Updated: Feb 14, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion
Changchun Li1, Chao Yang1, Guanghui Wei2
1Department of Pediatric Surgical Oncology, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, P.R. China.
Abstract:
Resistance is the major cause of cisplatin treatment failure in neuroblastoma (NB). Vandetanib is widely used in the treatment of several cancers. In the present study, we aimed to determine the potential of vandetanib in cisplatin‑resistant NB therapy. Immunohistochemistry (IHC) staining was employed to detect p‑RET and CXCR4 expression in cisplatin‑resistant or ‑sensitive NB tissues from patients. Vandetanib was added to treat selected cisplatin‑resistant SH‑SY5Y cells (SH‑SY5Y‑R); this was followed by CCK8 assay, colony formation assay, and invasion assay. Furthermore, the effect of vandetanib on subcutaneous tumor growth was investigated in mice. Our results demonstrated greater expression of p‑RET and CXCR4 in cisplatin‑resistant neuroblastomas (NBs). Vandetanib significantly inhibited SH‑SY5Y‑R cell proliferation, colony formation, and invasion, while downregulating p‑RET and CXCR4 expression. Furthermore, vandetanib was as effective as high‑dose cisplatin in impairing cisplatin‑resistant NB subcutaneous tumor growth. Notably, vandetanib caused less severe liver toxicity in mice compared with high‑dose cisplatin. In summary, this study identified Vandetanib as a potential drug for cisplatin‑resistant NB treatment.
Insights
Vandetanib shows promise for treating cisplatin-resistant neuroblastoma (NB). This drug inhibits cancer cell growth and invasion, offering a potentially less toxic alternative to high-dose cisplatin for NB therapy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Cisplatin resistance is a primary obstacle in neuroblastoma (NB) treatment.
- Vandetanib is an established therapeutic agent for various cancers.
Purpose of the Study:
- To evaluate the efficacy of Vandetanib in overcoming cisplatin resistance in neuroblastoma.
- To investigate the role of p-RET and CXCR4 in cisplatin-resistant NB.
Main Methods:
- Immunohistochemistry (IHC) to assess p-RET and CXCR4 expression in NB tissues.
- In vitro assays (CCK8, colony formation, invasion) on cisplatin-resistant SH-SY5Y cells.
- In vivo studies using mouse models to evaluate tumor growth and toxicity.
Main Results:
- Elevated p-RET and CXCR4 expression observed in cisplatin-resistant NB.
- Vandetanib treatment significantly reduced proliferation, colony formation, and invasion of resistant NB cells.
- Vandetanib demonstrated comparable efficacy to high-dose cisplatin in reducing tumor growth with lower liver toxicity.
Conclusions:
- Vandetanib effectively targets cisplatin-resistant neuroblastoma cells by downregulating p-RET and CXCR4.
- Vandetanib presents a promising therapeutic option for cisplatin-resistant NB, with a favorable toxicity profile.
Related Concept Videos
Feedback Inhibition
Resistivity
Resistance
Enzyme Inhibition
Population Growth
Inhibition of Cdk Activity

